FDA panel recommends keeping diabetes drug Avandia on the market

Avandia
Avandia

GlaxoSmithKline's diabetes drug Avandia should remain on the market but with new restrictions due to possible heart risks, says a federal panel of health experts.

The U.S. Food and Drug Administration advisers voted 20-12 to keep the medicine available -- 10 panelists also recommended limiting who can get and prescribe the drug. The FDA isn't required to follow the advice of its panels, but it often does. Once a drug that brought in billions in sales annually, Avandia's market share has plummeted in recent years after data showed a possible increase risk of heart attacks.